3C-like protease: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
 
CSV import
 
Line 31: Line 31:
[[Category:Proteases]]
[[Category:Proteases]]
[[Category:Coronaviruses]]
[[Category:Coronaviruses]]
<gallery>
File:DOI.10.1126.science.abb4489.S2.png|3C-like_protease
File:Nirtalmatrelvir_on_3CL.png|Nirtalmatrelvir bound to 3CL protease
File:PF-07321332.svg|Chemical structure of PF-07321332
File:Doi.10.1126.science.abb4489.F3.large.C.jpg|3C-like_protease
</gallery>

Latest revision as of 04:34, 18 February 2025

3C-like protease[edit]

The 3C-like protease (3CLpro), also known as the main protease (Mpro), is a key enzyme in the life cycle of coronaviruses. It is responsible for the cleavage of the viral polyprotein into functional units, which are essential for viral replication and transcription.

Structure[edit]

The 3C-like protease is a cysteine protease that typically forms a homodimer. Each monomer consists of three domains: domain I and II, which form a chymotrypsin-like fold, and domain III, which is involved in dimerization. The active site of the protease is located between domains I and II and contains a catalytic dyad composed of a cysteine and a histidine residue.

Function[edit]

The primary function of the 3C-like protease is to process the viral polyprotein by cleaving it at specific sites. This processing is crucial for the maturation of non-structural proteins that are necessary for the replication and transcription of the viral RNA genome. The protease recognizes specific cleavage sites characterized by a conserved sequence motif.

Inhibition[edit]

Inhibition of the 3C-like protease is a promising strategy for the development of antiviral drugs against coronaviruses. Inhibitors that target the active site of the protease can prevent the processing of the viral polyprotein, thereby halting viral replication. One such inhibitor is Nirmatrelvir, which has shown efficacy in inhibiting the activity of the 3C-like protease.

Drug Development[edit]

The development of drugs targeting the 3C-like protease involves the design of molecules that can bind to the active site and block its enzymatic activity. Structural studies, such as X-ray crystallography, have been instrumental in understanding the binding interactions between the protease and potential inhibitors. These studies guide the optimization of drug candidates to improve their potency and selectivity.

Related pages[edit]

Gallery[edit]